Breaking News Instant updates and real-time market news.

VRX

Valeant

$13.45

-0.02 (-0.15%)

12:32
05/19/17
05/19
12:32
05/19/17
12:32

Wells says generic Apriso competition may come much sooner than Valeant expected

After the U.S. Patent Office's Trials and Appeal Board ruled that patents related to Valeant's Apriso were unpatentable, Wells Fargo analyst David Maris said the decision may allow generic competition to the ulcerative colitis drug a "dozen years" earlier than Valeant anticipated. Valeant's 2016 10-K does not list Apriso as one of products the company sees facing generic competition between 2017 and 2021, noted Maris, who adds that it is possible that Valeant appeals the PTAB decision. Maris keeps an Underperform rating on Valeant shares.

  • 22

    May

  • 06

    Jun

  • 24

    Aug

VRX Valeant
$13.45

-0.02 (-0.15%)

05/19/17
DBAB
05/19/17
NO CHANGE
Target $18
DBAB
Hold
Deutsche Bank 'warming up' to Valeant story
In a research note titled "Warming up to VRX," Deutsche Bank analyst Gregg Gilbert says that while Valeant Pharmaceuticals is "not out of the woods," the worst fears may be subsiding. The analyst continues to view the company's near-term setup as "encouraging." Valeant's 2017 outlook seems reachable, asset sales in the near- and medium-term seem likely, and the recent refinancing provided more time and flexibility for the company to deal with its issues, Gilbert tells investors. He also believes the worst case for Xifaxan of near-term generic competition "seems to be off the table for now." The analyst keeps a Hold rating on Valeant with an $18 price target. The drugmaker closed yesterday up 22c to $13.47.
05/11/17
WELS
05/11/17
NO CHANGE
Target $9
WELS
Underperform
Valeant estimates reduced on weakening fundamentals at Wells Fargo
Wells Fargo analyst David Maris said the reaction to Valeant's guidance is too positive and notes leverage has increased, most businesses missed his forecasts, and the increase in EBITDA guidance was due to changes in how it accounts for foreign exchange. The analyst lowered estimates and reiterated his Underperform rating given the company's deteriorating fundamentals, adding that he expects the recent share strength to be temporary. However, he increased his price target on the shares to $9 from $8, noting Valeant's Q1 showed a "dramatic decline" in working capital.
05/09/17
JPMS
05/09/17
NO CHANGE
JPMS
Neutral
Valeant's road to recovery remains long, says JPMorgan
JPMorgan analyst Chris Schott finds today's rally in Valeant Pharmaceuticals unsurprising as EBITDA guidance was raised following significant cuts over the past year. That said, the analyst continues to see a "long road to recovery for the story." He keeps a Neutral rating on the shares. Valeant is up 18%, or $1.79, to $11.50 in midday trading.
05/09/17
WELS
05/09/17
NO CHANGE
WELS
Underperform
Valeant key products continue to underperform, says Wells Fargo
Following the company's Q1 results, Wells Fargo analyst David Maris says Valeant Pharmaceuticals' key products continue to underperform. Valeant's decision to highlight in its press release the EBITDA raise of 1.3% is understandable, as this is better than the recent trend, but the $50M raise is relative to approximately $28.9B of total debt, Maris tells investors in a research note. Key products and areas such as Xifaxan and Bausch + Lomb continue to underperform, the analyst contends. He keeps an Underperform rating on Valeant with an $8 price target. The stock in morning trading is up 15%, or $1.48, to $11.19.

TODAY'S FREE FLY STORIES

HYGS

Hydrogenics

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Conference/Events
TMX Group to hold a conference »

TSX Industrial &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 16

    Nov

THR

Thermon Group

$21.40

0.4 (1.90%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Recommendations
Thermon Group analyst commentary  »

Thermon Group price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGA

Pegasystems

$59.15

-0.3 (-0.50%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Recommendations
Pegasystems analyst commentary  »

Pegasystems should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$386.58

-3.12 (-0.80%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Technical Analysis
Technical View: Sherwin-Williams slips lower after results »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

ELVT

Elevate Credit

$7.52

-0.14 (-1.83%)

, FPAY

FlexShopper

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Conference/Events
Stephens to hold meetings at conference »

Stephens Hosted Company…

ELVT

Elevate Credit

$7.52

-0.14 (-1.83%)

FPAY

FlexShopper

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

CTMX

CytomX Therapeutics

$20.04

-0.12 (-0.60%)

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Initiation
CytomX Therapeutics initiated  »

CytomX Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$171.27

-3.71 (-2.12%)

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Periodicals
Facebook faces EU-wide privacy fights after top court setback, Bloomberg says »

Facebook may faces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

HFC

HollyFrontier

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Downgrade
HollyFrontier rating change  »

HollyFrontier downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PBF

PBF Energy

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Downgrade
PBF Energy rating change  »

PBF Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPX

Louisiana-Pacific

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Initiation
Louisiana-Pacific initiated  »

Louisiana-Pacific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VLO

Valero

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Downgrade
Valero rating change  »

Valero downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

DK

Delek US

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Upgrade
Delek US rating change  »

Delek US upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

ALDW

Alon USA Partners

$11.74

0.05 (0.43%)

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Upgrade
Alon USA Partners rating change  »

Alon USA Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Conference/Events
Drug Information Association to hold a conference »

Biosimilars Conference is…

PEBO

Peoples Bancorp

$33.03

-0.79 (-2.34%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Earnings
Peoples Bancorp reports Q3 EPS 60c, consensus 50c »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

WY

Weyerhaeuser

$34.82

-0.46 (-1.30%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Initiation
Weyerhaeuser initiated  »

Weyerhaeuser initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

ALXN

Alexion

$135.21

-3.81 (-2.74%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Recommendations
Alexion analyst commentary  »

Alexion could be up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 06

    Nov

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Hot Stocks
Breaking Hot Stocks news story on Pentair »

Pentair: Separation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Earnings
Pentair sees FY17 adjusted EPS $3.53, consensus $3.51 »

Sees FY17 sales $4.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Earnings
Pentair sees Q4 adjusted EPS approx. 93c, consensus 93c »

Sees Q4 revenue approx.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UFS

Domtar

$44.14

-0.23 (-0.52%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Initiation
Domtar initiated  »

Domtar initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

ADDYY

adidas

$109.85

-0.45 (-0.41%)

07:11
10/24/17
10/24
07:11
10/24/17
07:11
Initiation
adidas initiated  »

adidas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABG

Asbury Automotive

$56.05

0.2 (0.36%)

07:11
10/24/17
10/24
07:11
10/24/17
07:11
Earnings
Asbury Automotive reports Q3 EPS $1.48 with items, consensus $1.51 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:11
10/24/17
10/24
07:11
10/24/17
07:11
Earnings
Pentair reports Q3 adjusted EPS 95c, consensus 93c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:10
10/24/17
10/24
07:10
10/24/17
07:10
Hot Stocks
Pentair announces new electrical company nVent »

Pentair plc unveiled the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.